Effect of an EAA/Whey Composition on Protein Metabolism

NCT ID: NCT03502941

Last Updated: 2021-11-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-20

Study Completion Date

2019-07-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcopenia, a progressive loss of muscle mass, strength and function, is an inevitable natural process of aging. While it may be impossible to completely reverse the progress of sarcopenia, it is well established that intake of dietary protein through essential amino acids (EAAs) and whey protein increases anabolic response. The current study will test if a specially formulated mixture of EAAs and whey protein can maximally stimulate anabolic responses at the levels of whole body and muscle compared to whey protein alone.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The product composition is protected by intellectual property. It contains a combination of ingredients designed to stimulate anabolic responses at whole body and muscle and to ultimately induce long-term improvements in muscle function and size. EAAs are the only dietary macronutrients that are required for survival. They are "essential" because the body cannot produce them. There are 9 dietary EAAs while there are 11 dietary non-essential amino acids that are not required in the diet because they can be produced in the body. The composition is based on a blend of 8 of the 9 EAAs. In addition to being the "active" components of dietary protein, EAAs also have the advantage over intact protein including whey protein because free EAAs are absorbed from the intestine more quickly and more completely than amino acids contained in protein, which requires digestion before absorption indicating that intact protein is relatively slowly absorbed. Therefore, the combination of free EAAs and intact protein give not only an immediate response (from the free EAAs) but also a prolonged response (from the intact protein) over time by the slower digestion. The idea of combining a specific formulation of EAAs with an intact protein to obtain both an immediate as well as a more sustained response in protein anabolism is novel. Investigators propose that consumption of the EAA/protein composition will stimulate the net protein balance at the whole body level in a dose-dependent manner. The investigators further propose that the magnitude of increase in the net protein balance will be greater than induced by the consumption of the same amount of whey protein isolate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Arm 1 and 2: Crossover design for two different doses of the product (\~6.3 and 12.6 g of active components).

Arm 3: Parallel comparison equal to the double dose of whey protein isolate (12.6 g)
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A single dose of EAAs/whey

Subjects will consume 6.3 g of EAAs/whey in \~12 oz water.

Group Type EXPERIMENTAL

6.3 g of EAAs mixture and whey protein isolate

Intervention Type DIETARY_SUPPLEMENT

A single dose of the mixture of EAAs/whey

A double dose of EAAs/whey

Subjects will consume 12.6 g of EAAs/whey in \~12 oz water

Group Type EXPERIMENTAL

12.6 g of EAAs mixture and whey protein isolate

Intervention Type DIETARY_SUPPLEMENT

A double dose of the mixture of EAAs/whey

Whey protein alone

Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.

Group Type EXPERIMENTAL

12.6 g of whey protein isolate

Intervention Type DIETARY_SUPPLEMENT

Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

6.3 g of EAAs mixture and whey protein isolate

A single dose of the mixture of EAAs/whey

Intervention Type DIETARY_SUPPLEMENT

12.6 g of EAAs mixture and whey protein isolate

A double dose of the mixture of EAAs/whey

Intervention Type DIETARY_SUPPLEMENT

12.6 g of whey protein isolate

Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Essential Blends, Fairbanks, Alaska (AK), and Pure Protein, Bayport, New York (NY) Essential Blends, Fairbanks, AK, and Pure Protein, Bayport, NY Pure Protein, Bayport, NY

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI between 20 and 30 kg/m\^2

Exclusion Criteria

* Current diagnosis of diabetes
* History of malignancy in the 6 months prior to enrollment
* Weight reduction surgery
* Chronic inflammatory (Lupus, HIV/AIDS)
* Currently pregnant females
* Unable to eat dairy protein
* Unable to stop eating protein or Amino Acid (AA) supplements during the participation
* Regular resistance training (\> once per week)
* Concomitant use of corticosteroids (ingestion, injection or transdermal)
* Subjects who cannot safely stop using aspirin for 7 days prior to muscle biopsies
* Hemoglobin less than 9.5 g/dL, and platelets less than 150,000 at the screening visit
* Any other disease or condition placing the subject at increased risk of harm if they were to participate, at the discretion of the study physician
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Arkansas

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arny A Ferrando, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Arkansas

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Park S, Church DD, Azhar G, Schutzler SE, Ferrando AA, Wolfe RR. Anabolic response to essential amino acid plus whey protein composition is greater than whey protein alone in young healthy adults. J Int Soc Sports Nutr. 2020 Feb 10;17(1):9. doi: 10.1186/s12970-020-0340-5.

Reference Type DERIVED
PMID: 32041644 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

217658

Identifier Type: -

Identifier Source: org_study_id